What is a stock summary page? Click here for an overview.
Business Description
ProPhase Labs Inc
NAICS : 541380
SIC : 8734
ISIN : US74345W1080
Description
ProPhase Labs Inc is a diversified company that offers a range of services including diagnostic testing, genomics testing and contract manufacturing. Its operating segments include Diagnostic services and Consumer products. The Diagnostic segment provides COVID-19 diagnostic information services to a broad range of customers in the United States, including health plans, third-party payers and government organizations. The Consumer products segment is engaged in the research, development, manufacture, distribution, marketing and sale of OTC consumer healthcare products and dietary supplements in the United States and also provide personal genomics products and services.
Financial Strength
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.02 | |||||
| Equity-to-Asset | 0.42 | |||||
| Debt-to-Equity | 0.78 | |||||
| Debt-to-EBITDA | -1.09 | |||||
| Piotroski F-Score | 1/9 | |||||
| Altman Z-Score | -1.19 | |||||
| Beneish M-Score | -3 | |||||
| WACC vs ROIC | ||||||
Growth Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 27.2 | |||||
| 3-Year EBITDA Growth Rate | -85.5 | |||||
| 3-Year EPS without NRI Growth Rate | -45.4 | |||||
| 3-Year FCF Growth Rate | -31.7 | |||||
| 3-Year Book Growth Rate | 44.3 |
Momentum Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 60.77 | |||||
| 9-Day RSI | 54.64 | |||||
| 14-Day RSI | 51.39 | |||||
| 3-1 Month Momentum % | -15.22 | |||||
| 6-1 Month Momentum % | -75.72 | |||||
| 12-1 Month Momentum % | -90.85 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 1.47 | |||||
| Quick Ratio | 1.33 | |||||
| Cash Ratio | 0.02 | |||||
| Days Inventory | 88.58 | |||||
| Days Sales Outstanding | 1021.82 | |||||
| Days Payable | 240.82 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -15.9 | |||||
| Shareholder Yield % | -134.52 |
Profitability Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | -32.39 | |||||
| Operating Margin % | -277.69 | |||||
| Net Margin % | -217.64 | |||||
| FCF Margin % | -130.41 | |||||
| ROE % | -59.59 | |||||
| ROA % | -30.23 | |||||
| ROIC % | -34.61 | |||||
| 3-Year ROIIC % | -21.91 | |||||
| ROC (Joel Greenblatt) % | -80.01 | |||||
| ROCE % | -51.6 | |||||
| Years of Profitability over Past 10-Year | 3 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Forward PE Ratio | 0.84 | |||||
| Shiller PE Ratio | 3.3 | |||||
| PS Ratio | 0.54 | |||||
| PB Ratio | 0.21 | |||||
| Price-to-Tangible-Book | 0.36 | |||||
| EV-to-EBIT | -1.12 | |||||
| EV-to-Forward-EBIT | 10.42 | |||||
| EV-to-EBITDA | -1.44 | |||||
| EV-to-Revenue | 3.08 | |||||
| EV-to-Forward-Revenue | 1.84 | |||||
| EV-to-FCF | -2.46 | |||||
| Price-to-GF-Value | 0.37 | |||||
| Earnings Yield (Greenblatt) % | -89.29 | |||||
| FCF Yield % | -128.22 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:PRPH
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
ProPhase Labs Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 12.753 | ||
| EPS (TTM) ($) | -1.54 | ||
| Beta | -1.24 | ||
| 3-Year Sharpe Ratio | -0.43 | ||
| 3-Year Sortino Ratio | -0.57 | ||
| Volatility % | 135.98 | ||
| 14-Day RSI | 51.39 | ||
| 14-Day ATR ($) | 0.074857 | ||
| 20-Day SMA ($) | 0.412275 | ||
| 12-1 Month Momentum % | -90.85 | ||
| 52-Week Range ($) | 0.2179 - 7.48 | ||
| Shares Outstanding (Mil) | 30.23 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 1 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
ProPhase Labs Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
ProPhase Labs Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| No Event Data | ||||
ProPhase Labs Inc Frequently Asked Questions
What is ProPhase Labs Inc(PRPH)'s stock price today?
The current price of PRPH is $0.43. The 52 week high of PRPH is $7.48 and 52 week low is $0.22.
When is next earnings date of ProPhase Labs Inc(PRPH)?
The next earnings date of ProPhase Labs Inc(PRPH) is 2025-05-09 Est..
Does ProPhase Labs Inc(PRPH) pay dividends? If so, how much?
ProPhase Labs Inc(PRPH) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers